



## Clinical trial results:

### An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients with Homozygous Familial Hypercholesterolemia

#### Summary

EudraCT number	2016-000411-32
Trial protocol	NL
Global end of trial date	23 July 2018

#### Results information

Result version number	v1 (current)
This version publication date	07 August 2019
First version publication date	07 August 2019

#### Trial information

##### Trial identification

Sponsor protocol code	R1500-CL-1331
-----------------------	---------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02265952
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Regeneron Pharmaceuticals, Inc.
Sponsor organisation address	777 Old Saw Mill River Road, Tarrytown, United States, 10591
Public contact	Clinical Trial Information, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com
Scientific contact	Clinical Trial Information, Regeneron Pharmaceuticals, Inc., clinicaltrials@regeneron.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	09 August 2018
Is this the analysis of the primary completion data?	No

---

Global end of trial reached?	Yes
Global end of trial date	23 July 2018
Was the trial ended prematurely?	No

---

Notes:

---

**General information about the trial**

---

Main objective of the trial:

The purpose of this study was to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by REGN1500 in subjects with Homozygous Familial Hypercholesterolemia (HoFH).

---

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with the International Conference on Harmonisation (ICH) guidelines for Good Clinical Practice (GCP) and applicable regulatory requirements.

---

Background therapy: -

---

Evidence for comparator: -

---

Actual start date of recruitment	04 February 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

---

Notes:

---

**Population of trial subjects**

---

**Subjects enrolled per country**

---

Country: Number of subjects enrolled	Canada: 3
Country: Number of subjects enrolled	United States: 4
Country: Number of subjects enrolled	Netherlands: 2
Worldwide total number of subjects	9
EEA total number of subjects	2

---

Notes:

---

**Subjects enrolled per age group**

---

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9
From 65 to 84 years	0

---

85 years and over	0
-------------------	---

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at five sites in United States, Canada and the Netherlands between 04 Feb 2015 and 23 Jul 2018. A total of 12 subjects were screened in the study. Out of 12 subjects, 9 subjects received the study treatment.

### Pre-assignment

Screening details:

This study consisted of 2 screening periods: 1st for main study and 2nd for open label extension (OLE) period. Subjects on stable background medical lipid-modifying therapy for at least 4 weeks prior to screening, or who didn't undergo lipid apheresis within 4 weeks prior to screening visit, were directly entered into a 2-week screening period.

### Period 1

Period 1 title	Main Study Period
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Arm title	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
-----------	--

Arm description:

Subjects received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled subjects received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Subjects were followed for a period of 24 weeks (through Week 26 [Day 183]) after the last dose of study drug in the main study period.

Arm type	Experimental
Investigational medicinal product name	REGN1500
Investigational medicinal product code	REGN1500
Other name	Evinacumab
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

Subjects received REGN1500 SC in the abdomen/ IV infusion in the main study period.

<b>Number of subjects in period 1</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Started	9
Completed	9

**Period 2**

Period 2 title	Open Label Extension (OLE) Period
Is this the baseline period?	No
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

**Arms**

<b>Arm title</b>	REGN1500 300 mg SC/20 mg/kg IV
------------------	--------------------------------

## Arm description:

Subjects received REGN1500 a SC injection of 300 mg at Week 26 (Day 183), 27 (Day 190), 28 (Day 197) and 29 (Day 204) followed by IV injection of 20 mg/kg at Week 38 (Day 267) and every 12 weeks starting at Week 58 (Day 407) through Week 178 (Day 1247) in open-label extension period. Subjects were to be followed for a period of 24 weeks (through Week 214 [Day 1499]) after the last dose of study drug in the OLE treatment period.

Arm type	Experimental
Investigational medicinal product name	REGN1500
Investigational medicinal product code	REGN1500
Other name	Evinacumab
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use, Subcutaneous use

## Dosage and administration details:

Subjects received REGN1500 SC in the abdomen/ IV infusion in the open-label treatment period.

<b>Number of subjects in period 2<sup>[1]</sup></b>	REGN1500 300 mg SC/20 mg/kg IV
Started	8
Completed	0
Not completed	8
Physician decision	7
Consent withdrawn by subject	1

## Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: One subject chose not to enroll in OLE period.

## Baseline characteristics

### Reporting groups

Reporting group title	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
-----------------------	--

Reporting group description:

Subjects received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled subjects received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Subjects were followed for a period of 24 weeks (through Week 26 [Day 183]) after the last dose of study drug in the main study period.

Reporting group values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC	Total	
Number of subjects	9	9	
Age categorical Units: Subjects			
< 45	7	7	
≥ 45 to < 65	2	2	
≥ 65 to < 75	0	0	
< 75	0	0	
Age continuous Units: years arithmetic mean standard deviation	35.9 ± 9.06	-	
Gender categorical Units: Subjects			
Female	4	4	
Male	5	5	
Ethnicity Units: Subjects			
Hispanic or Latino	3	3	
Not Hispanic or Latino	6	6	
Not Reported	0	0	
Race Units: Subjects			
White	7	7	
Black or African American	0	0	
Asian	0	0	
American Indian or Alaska Native	0	0	
Native Hawaiian or Other Pacific Islander	0	0	
Other	0	0	
Not Reported	2	2	
Baseline Low-Density Lipoprotein Cholesterol (LDL-C) Units: Milligram per Deciliter (mg/dL) arithmetic mean standard deviation	376.0 ± 240.85	-	
Baseline High-Density Lipoprotein			

Cholesterol (HDL-C) Units: mg/dL arithmetic mean standard deviation	38.8 ± 14.24	-	
Baseline Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) Units: mg/dL arithmetic mean standard deviation	392.1 ± 246.41	-	
Baseline Apolipoprotein B (Apo B) Units: mg/dL arithmetic mean standard deviation	226.1 ± 131.70	-	
Baseline Apolipoprotein CIII (Apo CIII) Units: mg/dL arithmetic mean standard deviation	7.976 ± 3.3747	-	
Baseline Triglyceride (TG) Units: mg/dL arithmetic mean standard deviation	80.0 ± 41.20	-	
Baseline Lipoprotein(a) (Lp[a]) Units: mg/dL arithmetic mean standard deviation	154.9 ± 109.25	-	
Baseline Total Cholesterol (Total -C) Units: mg/dL arithmetic mean standard deviation	430.9 ± 235.60	-	
Baseline Apolipoprotein A-1 (Apo A-1) Units: mg/dL arithmetic mean standard deviation	110.4 ± 23.74	-	

## End points

### End points reporting groups

Reporting group title	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
Reporting group description: Subjects received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled subjects received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Subjects were followed for a period of 24 weeks (through Week 26 [Day 183]) after the last dose of study drug in the main study period.	
Reporting group title	REGN1500 300 mg SC/20 mg/kg IV
Reporting group description: Subjects received REGN1500 a SC injection of 300 mg at Week 26 (Day 183), 27 (Day 190), 28 (Day 197) and 29 (Day 204) followed by IV injection of 20 mg/kg at Week 38 (Day 267) and every 12 weeks starting at Week 58 (Day 407) through Week 178 (Day 1247) in open-label extension period. Subjects were to be followed for a period of 24 weeks (through Week 214 [Day 1499]) after the last dose of study drug in the OLE treatment period.	

### Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) to Week 4 in the Main Study Period

End point title	Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) to Week 4 in the Main Study Period <sup>[1]</sup>
End point description: Percent change was reported for low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) up to week 4. LDL-C was measured using conventional units mg/dL. The efficacy analysis set included all subjects in the safety analysis set (SAF) who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.	
End point type	Primary
End point timeframe: Baseline (Week 0) up to Week 4	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No sensitivity analysis was completed for this study.	

End point values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)	-49.17 (± 23.136)			

### Statistical analyses

No statistical analyses for this end point



---

**Secondary: Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) to Week 4 in the Main Study Period**

---

End point title	Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) to Week 4 in the Main Study Period
-----------------	--

End point description:

Absolute change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) up to week 4 was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 4

---

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: mg/dL				
arithmetic mean (standard deviation)	-157.34 ( $\pm$ 89.590)			

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Week 2 to Week 4 in the Main Study Period**

---

End point title	Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Week 2 to Week 4 in the Main Study Period
-----------------	---

End point description:

Absolute change in low-density lipoprotein cholesterol (LDL-C) from week 2 to week 4 was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 2 to Week 4

---

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Milligram per Deciliter (mg/dL)				
arithmetic mean (standard deviation)	-63.63 ( $\pm$ 50.970)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Week 2 to Week 4 in the Main Study Period

End point title	Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Week 2 to Week 4 in the Main Study Period
-----------------	--

End point description:

Percent change was reported in low-density lipoprotein cholesterol (LDL-C) from week 2 to week 4. LDL-C was measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 2 to Week 4

End point values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)	-30.05 (± 18.503)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) Over Time in the Main Study Period

End point title	Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) Over Time in the Main Study Period
-----------------	--

End point description:

Absolute change was reported in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) up to week 26. The efficacy analysis set included all subjects in the safety analysis set (SAF) who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 26

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: mg/dL				
arithmetic mean (standard deviation)				
Change at Day 4 (n= 9)	-39.60 (± 41.677)			
Change at Week 1 (n= 9)	-67.59 (± 46.041)			
Change at Week 2 (n= 9)	-93.71 (± 86.504)			
Change at Week 3 (n= 9)	-129.97 (± 90.533)			
Change at Week 4 (n= 9)	-157.34 (± 89.590)			
Change at Week 5 (n= 8)	-179.18 (± 101.260)			
Change at Week 6 (n= 9)	-183.41 (± 111.313)			
Change at Week 8 (n= 9)	-176.72 (± 118.441)			
Change at Week 10 (n= 9)	-151.19 (± 78.164)			
Change at Week 12 (n= 9)	-109.40 (± 74.108)			
Change at Week 13 (n= 2)	-170.15 (± 105.288)			
Change at Week 14 (n= 9)	-104.16 (± 78.954)			
Change at Week 15 (n= 2)	-186.15 (± 119.147)			
Change at Week 16 (n= 9)	-97.29 (± 179.016)			
Change at Week 17 (n= 2)	-174.20 (± 103.803)			
Change at Week 18 (n= 7)	-62.11 (± 167.004)			
Change at Week 20 (n= 2)	-155.25 (± 79.832)			
Change at Week 22 (n= 7)	-41.37 (± 169.432)			
Change at Week 23 (n= 2)	-155.85 (± 78.984)			
Change at Week 25 (n= 2)	-87.90 (± 23.900)			
Change at Week 26 (n= 6)	-23.98 (± 152.794)			

## Statistical analyses

**Secondary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) Over Time in the Main Study Period**

End point title	Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 0) Over Time in the Main Study Period
-----------------	---

## End point description:

Percent change was reported in low-density lipoprotein cholesterol (LDL-C) from baseline (week 0) up to week 26. LDL-C was measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline (Week 0) up to Week 26

End point values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)				
Percent change at Day 4 (n= 9)	-12.76 (± 11.086)			
Percent change at Week 1 (n= 9)	-24.00 (± 21.078)			
Percent change at Week 2 (n= 9)	-30.13 (± 24.402)			
Percent change at Week 3 (n= 9)	-41.38 (± 24.986)			
Percent change at Week 4 (n= 9)	-49.17 (± 23.136)			
Percent change at Week 5 (n= 8)	-46.88 (± 14.507)			
Percent change at Week 6 (n= 9)	-52.13 (± 14.768)			
Percent change at Week 8 (n= 9)	-51.59 (± 17.910)			
Percent change at Week 10 (n= 9)	-45.61 (± 13.839)			
Percent change at Week 12 (n= 9)	-36.54 (± 19.281)			
Percent change at Week 13 (n= 2)	-39.84 (± 10.753)			
Percent change at Week 14 (n= 9)	-33.02 (± 18.538)			
Percent change at Week 15 (n= 2)	-43.38 (± 12.814)			
Percent change at Week 16 (n= 9)	-24.98 (± 25.441)			
Percent change at Week 17 (n= 2)	-40.99 (± 9.950)			
Percent change at Week 18 (n= 7)	-13.72 (± 28.424)			

Percent change at Week 20 (n= 2)	-37.17 (± 5.503)			
Percent change at Week 22 (n= 7)	-9.50 (± 38.456)			
Percent change at Week 23 (n= 2)	-37.37 (± 5.217)			
Percent change at Week 25 (n= 2)	-22.12 (± 2.537)			
Percent change at Week 26 (n= 6)	-10.27 (± 25.806)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Absolute Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period
-----------------	---

End point description:

Absolute change in low-density lipoprotein cholesterol (LDL-C) from baseline (week 26) up to week 214 was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for the endpoint at a given time point. (ET= Early Termination; EOS = End of Study)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 26) up to Week 214

End point values	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: mg/dL				
arithmetic mean (standard deviation)				
Change at Week 26 (n= 8)	261.34 (± 178.792)			
Change at Week 27 (n= 8)	-58.73 (± 56.992)			
Change at Week 28 (n= 8)	-88.16 (± 83.196)			
Change at Week 29 (n= 8)	-116.20 (± 102.219)			
Change at Week 30 (n= 7)	-87.80 (± 108.905)			
Change at Week 31 (n= 8)	-144.99 (± 130.764)			
Change at Week 32 (n= 8)	-159.16 (± 128.072)			
Change at Week 34 (n= 8)	-128.38 (± 108.331)			

Change at Week 36 (n= 8)	-105.94 (± 89.990)			
Change at Week 38 (n= 8)	-79.98 (± 97.851)			
Change at Week 39 (n= 6)	-138.28 (± 123.133)			
Change at Week 40 (n= 6)	-127.13 (± 122.808)			
Change at Week 41 (n= 6)	-163.28 (± 137.365)			
Change at Week 42 (n= 6)	-142.65 (± 126.647)			
Change at Week 44 (n= 8)	-140.36 (± 109.275)			
Change at Week 46 (n= 8)	-123.25 (± 112.503)			
Change at Week 50 (n= 8)	-106.61 (± 99.458)			
Change at Week 54 (n= 8)	-13.38 (± 177.649)			
Change at Week 58 (n= 6)	-48.27 (± 93.443)			
Change at Week 70 (n= 4)	-117.93 (± 145.917)			
Change at Week 82 (n= 4)	-63.88 (± 64.738)			
Change at Week 94 (n= 1)	-369.90 (± 99999)			
Change at Week 106 (n= 1)	-290.00 (± 99999)			
Change at ET (n= 8)	-9.78 (± 64.930)			
Change at EOS (n= 3)	95.63 (± 147.100)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period
-----------------	--

End point description:

Percent change was reported in low-density lipoprotein cholesterol (LDL-C) from baseline (week 26) to week 214 in the OLE period. LDL-C was measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had at least 1 post-baseline measure of the lipid panel in the main study period. Here "n" signifies those subjects who were evaluable for this endpoint at a given time point. (ET= Early Termination; EOS = End of Study)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 26) up to Week 214

<b>End point values</b>	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percent Change				
arithmetic mean (standard deviation)				
Baseline (n= 8)	261.34 (± 178.792)			
Percent change at Week 27 (n= 8)	-22.49 (± 16.520)			
Percent change at Week 28 (n= 8)	-36.74 (± 20.931)			
Percent change at Week 29 (n= 8)	-44.35 (± 20.817)			
Percent change at Week 30 (n= 7)	-37.37 (± 31.297)			
Percent change at Week 31 (n= 8)	-50.74 (± 20.147)			
Percent change at Week 32 (n= 8)	-60.03 (± 18.502)			
Percent change at Week 34 (n= 8)	-53.03 (± 22.130)			
Percent change at Week 36 (n= 8)	-47.90 (± 21.623)			
Percent change at Week 38 (n= 8)	-37.05 (± 25.341)			
Percent change at Week 39 (n= 6)	-59.83 (± 22.220)			
Percent change at Week 40 (n= 6)	-53.90 (± 20.970)			
Percent change at Week 41 (n= 6)	-66.28 (± 18.555)			
Percent change at Week 42 (n= 6)	-59.59 (± 18.950)			
Percent change at Week 44 (n= 8)	-57.64 (± 18.599)			
Percent change at Week 46 (n= 8)	-48.74 (± 19.717)			
Percent change at Week 50 (n= 8)	-42.31 (± 23.194)			
Percent change at Week 54 (n= 8)	-13.60 (± 44.339)			
Percent change at Week 58 (n= 6)	-12.86 (± 27.645)			
Percent change at Week 70 (n= 4)	-38.61 (± 36.151)			
Percent change at Week 82 (n= 4)	-24.68 (± 30.789)			
Percent change at Week 94 (n= 1)	-81.67 (± 99999)			
Percent change at Week 106 (n= 1)	-64.03 (± 99999)			
Percent change at ET (n= 8)	-17.65 (± 28.813)			
Percent change at EOS (n= 3)	19.59 (± 40.976)			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 0) up to Week 26 in the Main Study

End point title	Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 0) up to Week 26 in the Main Study Period
-----------------	--

End point description:

Absolute change was reported for Apo B, Non-HDL-C, Total-C, and Lp(a) from baseline (week 0) up to Week 26. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 26

End point values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: mg/dL				
arithmetic mean (standard deviation)				
Apo B: Change at Week 2 (n = 9)	-53.0 (± 56.29)			
Apo B: Change at Week 3 (n = 9)	-81.0 (± 54.97)			
Apo B: Change at Week 4 (n = 9)	-96.3 (± 56.01)			
Apo B: Change at Week 5 (n = 8)	-104.6 (± 61.43)			
Apo B: Change at Week 6 (n = 9)	-100.7 (± 71.12)			
Apo B: Change at Week 8 (n = 9)	-96.8 (± 67.36)			
Apo B: Change at Week 12 (n = 9)	-60.0 (± 63.61)			
Apo B: Change at Week 14 (n = 9)	-61.7 (± 64.18)			
Apo B: Change at Week 16 (n = 9)	-62.6 (± 98.77)			
Apo B: Change at Week 18 (n = 7)	-28.6 (± 80.58)			
Apo B: Change at Week 20 (n = 2)	-114.0 (± 67.88)			
Apo B: Change at Week 22 (n = 7)	-22.7 (± 77.82)			
Apo B: Change at Week 23 (n = 2)	-119.0 (± 79.20)			
Apo B: Change at Week 26 (n = 6)	-4.7 (± 68.52)			
Non-HDL-C: Change at Day 4 (n = 9)	-44.61 (± 42.322)			



Non-HDL-C: Change at Week 1 (n = 9)	-72.16 (± 46.480)			
Non-HDL-C: Change at Week 2 (n = 9)	-97.12 (± 88.026)			
Non-HDL-C: Change at Week 3 (n = 9)	-138.09 (± 91.574)			
Non-HDL-C: Change at Week 4 (n = 9)	-165.64 (± 93.130)			
Non-HDL-C: Change at Week 5 (n = 8)	-187.46 (± 104.826)			
Non-HDL-C: Change at Week 6 (n = 9)	-191.20 (± 116.337)			
Non-HDL-C: Change at Week 8 (n = 9)	-182.98 (± 121.701)			
Non-HDL-C: Change at Week 10 (n = 9)	-156.98 (± 81.636)			
Non-HDL-C: Change at Week 12 (n = 9)	-116.20 (± 77.582)			
Non-HDL-C: Change at Week 13 (n = 2)	-180.25 (± 116.178)			
Non-HDL-C: Change at Week 14 (n = 9)	-108.58 (± 83.773)			
Non-HDL-C: Change at Week 15 (n = 2)	-196.85 (± 135.270)			
Non-HDL-C: Change at Week 16 (n = 9)	-99.58 (± 186.796)			
Non-HDL-C: Change at Week 17 (n = 2)	-185.40 (± 114.834)			
Non-HDL-C: Change at Week 18 (n = 7)	-60.41 (± 169.805)			
Non-HDL-C: Change at Week 20 (n = 2)	-161.90 (± 85.843)			
Non-HDL-C: Change at Week 22 (n = 7)	-41.16 (± 175.121)			
Non-HDL-C: Change at Week 23 (n = 2)	-163.25 (± 85.065)			
Non-HDL-C: Change at Week 25 (n = 2)	-92.20 (± 29.981)			
Non-HDL-C: Change at Week 26 (n = 6)	-25.47 (± 156.948)			
Total-C: Change at Day 4 (n = 9)	-50.36 (± 41.860)			
Total-C: Change at Week 1 (n = 9)	-81.99 (± 46.513)			
Total-C: Change at Week 2 (n = 9)	-109.03 (± 86.365)			
Total-C: Change at Week 3 (n = 9)	-154.10 (± 86.927)			
Total-C: Change at Week 4 (n = 9)	-180.79 (± 87.304)			
Total-C: Change at Week 5 (n = 8)	-199.11 (± 98.202)			
Total-C: Change at Week 6 (n = 9)	-207.63 (± 107.187)			
Total-C: Change at Week 8 (n = 9)	-195.18 (± 113.993)			
Total-C: Change at Week 10 (n = 9)	-167.87 (± 76.914)			
Total-C: Change at Week 12 (n = 9)	-122.94 (± 76.104)			
Total-C: Change at Week 13 (n = 2)	-188.45 (± 113.349)			

Total-C: Change at Week 14 (n = 9)	-114.68 (± 84.082)			
Total-C: Change at Week 15 (n = 2)	-205.60 (± 136.047)			
Total-C: Change at Week 16 (n = 9)	-105.24 (± 186.103)			
Total-C: Change at Week 17 (n = 2)	-195.00 (± 111.157)			
Total-C: Change at Week 18 (n = 7)	-63.27 (± 166.911)			
Total-C: Change at Week 20 (n = 2)	-170.45 (± 78.135)			
Total-C: Change at Week 22 (n = 7)	-41.30 (± 174.597)			
Total-C: Change at Week 23 (n = 2)	-167.55 (± 80.539)			
Total-C: Change at Week 25 (n = 2)	-90.15 (± 26.234)			
Total-C: Change at Week 26 (n = 6)	-30.77 (± 156.736)			
Lp(a): Change at Week 2 (n = 9)	-22.4 (± 30.18)			
Lp(a): Change at Week 3 (n = 9)	-20.8 (± 30.11)			
Lp(a): Change at Week 4 (n = 9)	-21.1 (± 28.29)			
Lp(a): Change at Week 5 (n = 8)	-30.1 (± 24.91)			
Lp(a): Change at Week 6 (n = 9)	-25.0 (± 31.40)			
Lp(a): Change at Week 8 (n = 9)	-28.9 (± 23.81)			
Lp(a): Change at Week 12 (n = 9)	-20.9 (± 16.30)			
Lp(a): Change at Week 14 (n = 9)	-22.3 (± 21.01)			
Lp(a): Change at Week 16 (n = 9)	-26.9 (± 38.97)			
Lp(a): Change at Week 18 (n = 7)	-29.9 (± 29.27)			
Lp(a): Change at Week 20 (n = 2)	-19.0 (± 46.67)			
Lp(a): Change at Week 22 (n = 7)	-24.3 (± 37.53)			
Lp(a): Change at Week 23 (n = 2)	-12.5 (± 19.09)			
Lp(a): Change at Week 26 (n = 6)	-16.3 (± 37.90)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 0) up to Week 26 in the Main Study Period

End point title	Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-
-----------------	---

End point description:

Percent change was reported for Apo B, Non-HDL-C, Total-C, and Lp(a) from baseline (week 0) up to week 26. Apo B, Non-HDL-C, Total-C, and Lp(a) were measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point.

End point type Secondary

End point timeframe:

Baseline (Week 0) up to Week 26

End point values	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)				
Apo B: Percent change at Week 2 (n = 9)	-24.38 (± 20.959)			
Apo B: Percent change at Week 3 (n = 9)	-38.63 (± 22.114)			
Apo B: Percent change at Week 4 (n = 9)	-45.89 (± 18.222)			
Apo B: Percent change at Week 5 (n = 8)	-42.28 (± 13.247)			
Apo B: Percent change at Week 6 (n = 9)	-43.12 (± 14.716)			
Apo B: Percent change at Week 8 (n = 9)	-42.66 (± 14.475)			
Apo B: Percent change at Week 12 (n = 9)	-29.47 (± 21.736)			
Apo B: Percent change at Week 14 (n = 9)	-27.42 (± 18.418)			
Apo B: Percent change at Week 16 (n = 9)	-21.60 (± 24.970)			
Apo B: Percent change at Week 18 (n = 7)	-7.63 (± 24.347)			
Apo B: Percent change at Week 20 (n = 2)	-39.32 (± 6.481)			
Apo B: Percent change at Week 22 (n = 7)	-8.07 (± 30.444)			
Apo B: Percent change at Week 23 (n = 2)	-40.29 (± 10.089)			
Apo B: Percent change at Week 26 (n = 6)	-2.03 (± 25.320)			
Non-HDL-C: Percent change at Day 4 (n = 9)	-13.61 (± 10.721)			
Non-HDL-C: Percent change at Week 1 (n = 9)	-24.12 (± 20.083)			
Non-HDL-C: Percent change at Week 2 (n = 9)	-29.61 (± 23.406)			
Non-HDL-C: Percent change at Week 3 (n = 9)	-41.62 (± 23.969)			

Non-HDL-C: Percent change at Week 4 (n = 9)	-48.91 (± 22.257)			
Non-HDL-C: Percent change at Week 5 (n = 8)	-46.61 (± 14.172)			
Non-HDL-C: Percent change at Week 6 (n = 9)	-51.49 (± 14.344)			
Non-HDL-C: Percent change at Week 8 (n = 9)	-50.65 (± 17.231)			
Non-HDL-C: Percent change at Week 10 (n = 9)	-44.80 (± 13.148)			
Non-HDL-C: Percent change at Week 12 (n = 9)	-36.40 (± 18.711)			
Non-HDL-C: Percent change at Week 13 (n = 2)	-39.84 (± 11.313)			
Non-HDL-C: Percent change at Week 14 (n = 9)	-32.71 (± 18.214)			
Non-HDL-C: Percent change at Week 15 (n = 2)	-43.09 (± 14.482)			
Non-HDL-C: Percent change at Week 16 (n = 9)	-24.22 (± 25.899)			
Non-HDL-C: Percent change at Week 17 (n = 2)	-41.21 (± 10.455)			
Non-HDL-C: Percent change at Week 18 (n = 7)	-12.70 (± 27.798)			
Non-HDL-C: Percent change at Week 20 (n = 2)	-36.71 (± 5.471)			
Non-HDL-C: Percent change at Week 22 (n = 7)	-9.43 (± 37.102)			
Non-HDL-C: Percent change at Week 23 (n = 2)	-37.10 (± 5.138)			
Non-HDL-C: Percent change at Week 25 (n = 2)	-21.86 (± 1.676)			
Non-HDL-C: Percent change at Week 26 (n = 6)	-9.99 (± 25.292)			
Total-C: Percent change at Day 4 (n = 9)	-13.18 (± 8.932)			
Total-C: Percent change at Week 1 (n = 9)	-23.23 (± 16.602)			
Total-C: Percent change at Week 2 (n = 9)	-29.14 (± 20.307)			
Total-C: Percent change at Week 3 (n = 9)	-40.81 (± 21.011)			
Total-C: Percent change at Week 4 (n = 9)	-46.95 (± 19.083)			
Total-C: Percent change at Week 5 (n = 8)	-45.43 (± 12.909)			
Total-C: Percent change at Week 6 (n = 9)	-50.68 (± 13.327)			
Total-C: Percent change at Week 8 (n = 9)	-48.29 (± 15.556)			
Total-C: Percent change at Week 10 (n = 9)	-42.15 (± 10.858)			
Total-C: Percent change at Week 12 (n = 9)	-33.48 (± 16.136)			
Total-C: Percent change at Week 13 (n = 2)	-38.98 (± 10.525)			
Total-C: Percent change at Week 14 (n = 9)	-29.66 (± 15.759)			
Total-C: Percent change at Week 15 (n = 2)	-42.01 (± 14.356)			
Total-C: Percent change at Week 16 (n = 9)	-23.51 (± 25.208)			

Total-C: Percent change at Week 17 (n = 2)	-40.59 (± 9.468)			
Total-C: Percent change at Week 18 (n = 7)	-12.65 (± 26.105)			
Total-C: Percent change at Week 20 (n = 2)	-36.28 (± 3.862)			
Total-C: Percent change at Week 22 (n = 7)	-7.73 (± 33.729)			
Total-C: Percent change at Week 23 (n = 2)	-35.50 (± 4.662)			
Total-C: Percent change at Week 25 (n = 2)	-19.82 (± 1.459)			
Total-C: Percent change at Week 26 (n = 6)	-10.05 (± 22.903)			
Lp(a): Percent change at Week 2 (n = 9)	-11.64 (± 20.323)			
Lp(a): Percent change at Week 3 (n = 9)	-12.25 (± 19.350)			
Lp(a): Percent change at Week 4 (n = 9)	-10.85 (± 24.465)			
Lp(a): Percent change at Week 5 (n = 8)	-23.79 (± 17.908)			
Lp(a): Percent change at Week 6 (n = 9)	-17.12 (± 23.680)			
Lp(a): Percent change at Week 8 (n = 9)	-17.24 (± 17.764)			
Lp(a): Percent change at Week 12 (n = 9)	-13.09 (± 12.614)			
Lp(a): Percent change at Week 14 (n = 9)	-13.54 (± 10.151)			
Lp(a): Percent change at Week 16 (n = 9)	-16.93 (± 24.795)			
Lp(a): Percent change at Week 18 (n = 7)	-19.61 (± 21.686)			
Lp(a): Percent change at Week 20 (n = 2)	-19.72 (± 32.894)			
Lp(a): Percent change at Week 22 (n = 7)	-10.37 (± 29.230)			
Lp(a): Percent change at Week 23 (n = 2)	-10.62 (± 15.373)			
Lp(a): Percent change at Week 26 (n = 6)	3.46 (± 39.400)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Absolute Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period
-----------------	---

### End point description:

Absolute change in Apo B, Non-HDL-C, Total-C, and Lp(a) from baseline to week 214 in open label extension (OLE) period. The efficacy analysis set included all subjects in the SAF who had baseline and

at least one post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point. (ET = Early Termination; EOS = End of Study)

End point type	Secondary
End point timeframe:	
Baseline (Week 26) up to Week 214	

End point values	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: mg/dL				
arithmetic mean (standard deviation)				
Apo B: Change at Week 30 (n= 7)	-48.1 (± 61.41)			
Apo B: Change at Week 34 (n= 8)	-65.9 (± 58.96)			
Apo B: Change at Week 38 (n= 8)	-40.9 (± 56.34)			
Apo B: Change at Week 42 (n= 6)	-79.5 (± 71.19)			
Apo B: Change at Week 44 (n= 8)	-78.6 (± 58.93)			
Apo B: Change at Week 50 (n= 8)	-57.8 (± 50.82)			
Apo B: Change at Week 70 (n= 4)	-60.3 (± 78.24)			
Apo B: Change at Week 82 (n= 4)	-38.0 (± 35.66)			
Apo B: Change at Week 94 (n= 1)	-212.0 (± 99999)			
Apo B: Change at Week 106 (n= 1)	-173.0 (± 99999)			
Apo B: Change at ET (n= 8)	-3.5 (± 42.88)			
Apo B: Change at EOS (n= 3)	65.0 (± 100.53)			
Non- HDL-C: Change at Week 27 (n= 8)	-65.06 (± 61.756)			
Non- HDL-C: Change at Week 28 (n= 8)	-95.65 (± 87.499)			
Non- HDL-C: Change at Week 29 (n= 8)	-122.94 (± 106.296)			
Non- HDL-C: Change at Week 30 (n= 7)	-94.33 (± 113.286)			
Non- HDL-C: Change at Week 31 (n= 8)	-152.98 (± 135.977)			
Non- HDL-C: Change at Week 32 (n= 8)	-166.94 (± 133.990)			
Non- HDL-C: Change at Week 34 (n= 8)	-133.69 (± 112.247)			
Non- HDL-C: Change at Week 36 (n= 8)	-111.06 (± 93.635)			
Non- HDL-C: Change at Week 38 (n= 8)	-84.16 (± 101.210)			
Non- HDL-C: Change at Week 39 (n= 6)	-146.35 (± 128.368)			

Non- HDL-C: Change at Week 40 (n= 6)	-134.50 ( $\pm$ 128.198)			
Non- HDL-C: Change at Week 41 (n= 6)	-171.25 ( $\pm$ 143.692)			
Non- HDL-C: Change at Week 42 (n= 6)	-150.28 ( $\pm$ 132.214)			
Non- HDL-C: Change at Week 44 (n= 8)	-149.00 ( $\pm$ 114.152)			
Non- HDL-C: Change at Week 46 (n= 8)	-129.99 ( $\pm$ 116.770)			
Non- HDL-C: Change at Week 50 (n= 8)	-110.83 ( $\pm$ 104.353)			
Non- HDL-C: Change at Week 54 (n= 8)	-14.79 ( $\pm$ 178.797)			
Non- HDL-C: Change at Week 58 (n= 6)	-49.13 ( $\pm$ 97.212)			
Non- HDL-C: Change at Week 70 (n= 4)	-121.83 ( $\pm$ 152.887)			
Non- HDL-C: Change at Week 82 (n= 4)	-69.00 ( $\pm$ 66.715)			
Non- HDL-C: Change at Week 94 (n= 1)	-388.10 ( $\pm$ 99999)			
Non- HDL-C: Change at Week 106 (n= 1)	-303.10 ( $\pm$ 99999)			
Non- HDL-C: Change at ET (n= 8)	-12.45 ( $\pm$ 64.513)			
Non- HDL-C: Change at EOS (n= 3)	102.07 ( $\pm$ 153.301)			
Total-C: Change at Week 27 (n= 8)	-73.80 ( $\pm$ 60.737)			
Total-C: Change at Week 28 (n= 8)	-107.78 ( $\pm$ 83.051)			
Total-C: Change at Week 29 (n= 8)	-134.33 ( $\pm$ 102.667)			
Total-C: Change at Week 30 (n= 7)	-107.61 ( $\pm$ 109.689)			
Total-C: Change at Week 31 (n= 8)	-166.85 ( $\pm$ 130.925)			
Total-C: Change at Week 32 (n= 8)	-181.09 ( $\pm$ 130.048)			
Total-C: Change at Week 34 (n= 8)	-148.90 ( $\pm$ 106.534)			
Total-C: Change at Week 36 (n= 8)	-125.14 ( $\pm$ 89.065)			
Total-C: Change at Week 38 (n= 8)	-93.00 ( $\pm$ 99.558)			
Total-C: Change at Week 39 (n= 6)	-160.38 ( $\pm$ 125.452)			
Total-C: Change at Week 40 (n= 6)	-150.42 ( $\pm$ 124.695)			
Total-C: Change at Week 41 (n= 6)	-188.42 ( $\pm$ 141.249)			
Total-C: Change at Week 42 (n= 6)	-166.80 ( $\pm$ 128.247)			
Total-C: Change at Week 44 (n= 8)	-164.68 ( $\pm$ 110.222)			
Total-C: Change at Week 46 (n= 8)	-144.69 ( $\pm$ 110.682)			
Total-C: Change at Week 50 (n= 8)	-123.04 ( $\pm$ 99.299)			
Total-C: Change at Week 54 (n= 8)	-23.80 ( $\pm$ 180.982)			

Total-C: Change at Week 58 (n= 6)	-54.45 (± 97.160)			
Total-C: Change at Week 70 (n= 4)	-132.55 (± 152.664)			
Total-C: Change at Week 82 (n= 4)	-75.43 (± 67.802)			
Total-C: Change at Week 94 (n= 1)	-392.30 (± 99999)			
Total-C: Change at Week 106 (n= 1)	-303.10 (± 99999)			
Total-C: Change at ET (n= 8)	-20.38 (± 68.809)			
Total-C: Change at EOS (n= 3)	100.40 (± 144.828)			
Lp(a): Change at Week 30 (n= 7)	-9.0 (± 27.59)			
Lp(a): Change at Week 34 (n= 8)	-10.8 (± 24.00)			
Lp(a): Change at Week 38 (n= 8)	-16.0 (± 19.70)			
Lp(a): Change at Week 42 (n= 6)	-0.8 (± 41.36)			
Lp(a): Change at Week 44 (n= 8)	1.5 (± 37.73)			
Lp(a): Change at Week 50 (n= 8)	11.6 (± 48.23)			
Lp(a): Change at Week 70 (n= 4)	36.8 (± 77.92)			
Lp(a): Change at Week 82 (n= 4)	-5.3 (± 27.04)			
Lp(a): Change at Week 94 (n= 1)	-18.0 (± 99999)			
Lp(a): Change at Week 106 (n= 1)	39.0 (± 99999)			
Lp(a): Change at Week ET (n= 8)	11.6 (± 26.72)			
Lp(a): Change at EOS (n= 3)	18.3 (± 18.01)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Percent Change in Apolipoprotein (Apo B), Non-High-Density Lipoprotein Cholesterol (Non-HDL-C), Total Cholesterol (Total-C), and Lipoprotein(a) (Lp[a]) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period
-----------------	--

### End point description:

Percent change was reported in Apo B, Non-HDL-C, Total-C, and Lp(a) from baseline (week 26) up to week 214 in OLE Period. Apo B, Non-HDL-C, Total-C, and Lp(a) were measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least one post-baseline measure of the lipid panel in the main study period. Here "n" signifies the subjects who were evaluable for this endpoint at a given time point. (ET= Early Termination; EOS = End of Study)

End point type	Secondary
----------------	-----------

### End point timeframe:

Baseline (Week 26) up to Week 214



<b>End point values</b>	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percent change				
arithmetic mean (standard deviation)				
Apo B: Percent change at Week 30 (n= 7)	-30.59 (± 25.991)			
Apo B: Percent change at Week 34 (n= 8)	-41.27 (± 19.573)			
Apo B: Percent change at Week 38 (n= 8)	-29.02 (± 25.029)			
Apo B: Percent change at Week 42 (n= 6)	-50.90 (± 17.497)			
Apo B: Percent change at Week 44 (n= 8)	-48.59 (± 16.201)			
Apo B: Percent change at Week 50 (n= 8)	-36.68 (± 19.620)			
Apo B: Percent change at Week 70 (n= 4)	-33.44 (± 26.773)			
Apo B: Percent change at Week 82 (n= 4)	-24.87 (± 17.148)			
Apo B: Percent change at Week 94 (n= 1)	-77.09 (± 99999)			
Apo B: Percent change at Week 106 (n= 1)	-62.91 (± 99999)			
Apo B: Percent change at ET (n= 8)	-11.94 (± 25.708)			
Apo B: Percent change at EOS (n= 3)	22.60 (± 38.988)			
Non- HDL-C: Percent change at Week 27 (n= 8)	-23.62 (± 15.342)			
Non- HDL-C: Percent change at Week 28 (n= 8)	-37.22 (± 19.207)			
Non- HDL-C: Percent change at Week 29 (n= 8)	-44.30 (± 19.766)			
Non- HDL-C: Percent change at Week 30 (n= 7)	-37.90 (± 29.133)			
Non- HDL-C: Percent change at Week 31 (n= 8)	-50.59 (± 19.285)			
Non- HDL-C: Percent change at Week 32 (n= 8)	-59.09 (± 18.200)			
Non- HDL-C: Percent change at Week 34 (n= 8)	-51.55 (± 21.112)			
Non- HDL-C: Percent change at Week 36 (n= 8)	-46.62 (± 20.797)			
Non- HDL-C: Percent change at Week 38 (n= 8)	-36.10 (± 24.473)			
Non- HDL-C: Percent change at Week 39 (n= 6)	-59.25 (± 21.381)			
Non- HDL-C: Percent change at Week 40 (n= 6)	-53.24 (± 20.135)			
Non- HDL-C: Percent change at Week 41 (n= 6)	-65.07 (± 18.375)			
Non- HDL-C: Percent change at Week 42 (n= 6)	-58.92 (± 18.287)			
Non- HDL-C: Percent change at Week 44 (n= 8)	-57.03 (± 17.675)			
Non- HDL-C: Percent change at Week 46 (n= 8)	-48.27 (± 18.674)			

Non- HDL-C: Percent change at Week 50 (n= 8)	-41.16 (± 22.284)			
Non- HDL-C: Percent change at Week 54 (n= 8)	-12.93 (± 42.412)			
Non- HDL-C: Percent change at Week 58 (n= 6)	-12.28 (± 26.060)			
Non- HDL-C: Percent change at Week 70 (n= 4)	-37.68 (± 35.771)			
Non- HDL-C: Percent change at Week 82 (n= 4)	-26.16 (± 27.153)			
Non- HDL-C: Percent change at Week 94 (n= 1)	-81.52 (± 99999)			
Non- HDL-C: Percent change at Week 106 (n= 1)	-63.66 (± 99999)			
Non- HDL-C: Percent change at ET (n= 8)	-17.65 (± 27.339)			
Non- HDL-C: Percent change at EOS (n= 3)	19.98 (± 40.313)			
Total-C: Percent change at Week 27 (n= 8)	-22.24 (± 11.566)			
Total-C: Percent change at Week 28 (n= 8)	-34.78 (± 14.984)			
Total-C: Percent change at Week 29 (n= 8)	-40.57 (± 14.335)			
Total-C: Percent change at Week 30 (n= 7)	-36.37 (± 23.550)			
Total-C: Percent change at Week 31 (n= 8)	-48.83 (± 16.944)			
Total-C: Percent change at Week 32 (n= 8)	-55.05 (± 16.624)			
Total-C: Percent change at Week 34 (n= 8)	-48.67 (± 18.123)			
Total-C: Percent change at Week 36 (n= 8)	-44.16 (± 19.175)			
Total-C: Percent change at Week 38 (n= 8)	-33.29 (± 22.145)			
Total-C: Percent change at Week 39 (n= 6)	-54.40 (± 19.803)			
Total-C: Percent change at Week 40 (n= 6)	-50.13 (± 18.316)			
Total-C: Percent change at Week 41 (n= 6)	-60.87 (± 17.966)			
Total-C: Percent change at Week 42 (n= 6)	-54.88 (± 15.886)			
Total-C: Percent change at Week 44 (n= 8)	-53.41 (± 16.231)			
Total-C: Percent change at Week 46 (n= 8)	-46.06 (± 16.855)			
Total-C: Percent change at Week 50 (n= 8)	-39.04 (± 19.318)			
Total-C: Percent change at Week 54 (n= 8)	-12.82 (± 38.323)			
Total-C: Percent change at Week 58 (n= 6)	-13.78 (± 21.976)			
Total-C: Percent change at Week 70 (n= 4)	-36.63 (± 32.371)			
Total-C: Percent change at Week 82 (n= 4)	-23.09 (± 19.171)			
Total-C: Percent change at Week 94 (n= 1)	-77.50 (± 99999)			
Total-C: Percent change at Week 106 (n= 1)	-59.88 (± 99999)			

Total-C: Percent change at ET (n= 8)	-16.76 (± 25.085)			
Total-C: Percent change at EOS (n= 3)	18.20 (± 33.900)			
Lp(a): Percent change at Week 30 (n= 7)	-3.57 (± 24.610)			
Lp(a): Percent change at Week 34 (n= 8)	-6.43 (± 21.281)			
Lp(a): Percent change at Week 38 (n= 8)	-9.50 (± 14.429)			
Lp(a): Percent change at Week 42 (n= 6)	-4.76 (± 24.227)			
Lp(a): Percent change at Week 44 (n= 8)	-5.13 (± 25.377)			
Lp(a): Percent change at Week 50 (n= 8)	1.02 (± 29.756)			
Lp(a): Percent change at Week 70 (n= 4)	15.80 (± 36.280)			
Lp(a): Percent change at Week 82 (n= 4)	-3.77 (± 16.168)			
Lp(a): Percent change at Week 94 (n= 1)	-11.92 (± 99999)			
Lp(a): Percent change at Week 106 (n= 1)	25.83 (± 99999)			
Lp(a): Percent change at ET (n= 8)	9.96 (± 21.597)			
Lp(a): Percent change at EOS (n= 3)	40.51 (± 39.616)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% from Baseline (Week 0) in the Main Study Period

End point title	Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of ≥ 25% from Baseline (Week 0) in the Main Study Period
-----------------	---

End point description:

Percentage of subjects who achieved reduction in low-density lipoprotein cholesterol (LDL-C) of greater than or equal to (≥) 25 percent (%) from baseline in the main study period was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 26

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of subjects				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 25\%$ from Baseline (Week 26) in the Open Label Extension (OLE) Period

End point title	Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 25\%$ from Baseline (Week 26) in the Open Label Extension (OLE) Period
End point description:	Percentage of subjects who achieved a reduction in low-density lipoprotein cholesterol (LDL-C) of $\geq 25\%$ from baseline (week 26) to week 214 was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.
End point type	Secondary
End point timeframe:	Baseline (Week 26) to Week 214

<b>End point values</b>	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percentage of Subjects				
number (not applicable)	100			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 50\%$ from Baseline (Week 0) in the Main Study Period

End point title	Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 50\%$ from Baseline (Week 0) in the Main Study Period
End point description:	
Percentage of subjects who achieved a reduction in low-density lipoprotein cholesterol (LDL-C) of $\geq 50\%$ from baseline (week 0) to week 26 was reported. The efficacy analysis set included all subjects in the	

SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
End point timeframe:	
Baseline (Week 0) to Week 26	

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percentage of subjects				
number (not applicable)	77.8			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 50\%$ from Baseline (Week 26) in the Open Label Extension (OLE) Period

End point title	Percentage of Subjects Who Achieved Reduction in Low-Density Lipoprotein Cholesterol (LDL-C) of $\geq 50\%$ from Baseline (Week 26) in the Open Label Extension (OLE) Period
-----------------	--

End point description:

Percentage of subjects who achieved reduction in low-density lipoprotein cholesterol (LDL-C) of  $\geq 50\%$  from baseline (week 26) in the OLE period was reported. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period.

End point type	Secondary
End point timeframe:	
Baseline (Week 26) up to Week 214	

<b>End point values</b>	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percentage of subjects				
number (not applicable)	87.5			

### Statistical analyses

No statistical analyses for this end point

**Secondary: Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 0) Over Time in the Main Study Period**

End point title	Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 0) Over Time in the Main Study Period
-----------------	---

End point description:

Absolute change was reported in HDL-C, TG, and Apo A-1 from baseline (week 0) up to week 26. The efficacy analysis set included all subjects in the SAF who had baseline and at least one post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 0) up to Week 26

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: mg/dL				
arithmetic mean (standard deviation)				
HDL-C: Change at Day 4 (n = 9)	-5.81 (± 4.789)			
HDL-C: Change at Week 1 (n = 9)	-9.92 (± 6.578)			
HDL-C: Change at Week 2 (n = 9)	-11.99 (± 7.351)			
HDL-C: Change at Week 3 (n = 9)	-16.02 (± 10.737)			
HDL-C: Change at Week 4 (n = 9)	-15.07 (± 10.792)			
HDL-C: Change at Week 5 (n = 8)	-11.66 (± 8.442)			
HDL-C: Change at Week 6 (n = 9)	-16.46 (± 11.868)			
HDL-C: Change at Week 8 (n = 9)	-12.06 (± 11.334)			
HDL-C: Change at Week 10 (n = 9)	-10.94 (± 8.215)			
HDL-C: Change at Week 12 (n = 9)	-6.82 (± 6.811)			
HDL-C: Change at Week 13 (n = 2)	-8.10 (± 2.970)			
HDL-C: Change at Week 14 (n = 9)	-6.18 (± 4.205)			
HDL-C: Change at Week 15 (n = 2)	-8.70 (± 0.566)			
HDL-C: Change at Week 16 (n = 9)	-5.54 (± 5.785)			
HDL-C: Change at Week 17 (n = 2)	-9.40 (± 3.818)			
HDL-C: Change at Week 18 (n = 7)	-2.93 (± 7.435)			
HDL-C: Change at Week 20 (n = 2)	-8.70 (± 8.202)			

HDL-C: Change at Week 22 (n = 7)	-0.30 (± 6.943)			
HDL-C: Change at Week 23 (n = 2)	-4.00 (± 4.384)			
HDL-C: Change at Week 25 (n = 2)	2.50 (± 3.818)			
HDL-C: Change at Week 26 (n = 6)	-5.30 (± 5.266)			
TG: Change at Day 4 (n = 9)	-25.17 (± 18.545)			
TG: Change at Week 1 (n = 9)	-21.41 (± 17.603)			
TG: Change at Week 2 (n = 9)	-15.83 (± 15.908)			
TG: Change at Week 3 (n = 9)	-39.73 (± 31.977)			
TG: Change at Week 4 (n = 9)	-40.81 (± 30.277)			
TG: Change at Week 5 (n = 8)	-42.04 (± 28.887)			
TG: Change at Week 6 (n = 9)	-38.73 (± 35.120)			
TG: Change at Week 8 (n = 9)	-30.37 (± 26.383)			
TG: Change at Week 10 (n = 9)	-28.79 (± 21.095)			
TG: Change at Week 12 (n = 9)	-33.23 (± 32.901)			
TG: Change at Week 13 (n = 2)	-49.15 (± 56.922)			
TG: Change at Week 14 (n = 9)	-22.11 (± 35.348)			
TG: Change at Week 15 (n = 2)	-52.20 (± 82.590)			
TG: Change at Week 16 (n = 9)	-11.20 (± 48.136)			
TG: Change at Week 17 (n = 2)	-55.35 (± 58.195)			
TG: Change at Week 18 (n = 7)	9.77 (± 24.537)			
TG: Change at Week 20 (n = 2)	-33.65 (± 33.729)			
TG: Change at Week 22 (n = 7)	1.90 (± 33.916)			
TG: Change at Week 23 (n = 2)	-36.30 (± 31.254)			
TG: Change at Week 25 (n = 2)	-23.45 (± 34.436)			
TG: Change at Week 26 (n = 6)	-5.87 (± 28.748)			
Apo A-1: Change at Week 2 (n = 9)	-28.6 (± 18.64)			
Apo A-1: Change at Week 3 (n = 9)	-43.3 (± 22.54)			
Apo A-1: Change at Week 4 (n = 9)	-43.4 (± 16.88)			
Apo A-1: Change at Week 5 (n = 8)	-35.8 (± 17.53)			
Apo A-1: Change at Week 6 (n = 9)	-40.7 (± 19.86)			
Apo A-1: Change at Week 8 (n = 9)	-33.6 (± 20.64)			

Apo A-1: Change at Week 12 (n = 9)	-17.2 (± 20.04)			
Apo A-1: Change at Week 14 (n = 9)	-17.7 (± 11.97)			
Apo A-1: Change at Week 16 (n = 9)	-11.3 (± 16.50)			
Apo A-1: Change at Week 18 (n = 7)	-4.9 (± 17.72)			
Apo A-1: Change at Week 20 (n = 2)	-24.0 (± 8.49)			
Apo A-1: Change at Week 22 (n = 7)	1.9 (± 15.42)			
Apo A-1: Change at Week 23 (n = 2)	-23.0 (± 8.49)			
Apo A-1: Change at Week 26 (n = 6)	-10.8 (± 13.83)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 0) Over Time in the Main Study Period

End point title	Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 0) Over Time in the Main Study Period
End point description:	
Percent change was reported in HDL-C, TG, and Apo A-1 from baseline (week 0) up to week 26. HDL-C, TG, and Apo A-1 were measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies the subjects who were evaluable for this endpoint at a given time point.	
End point type	Secondary
End point timeframe:	
Baseline (Week 0) up to Week 26	

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)				
HDL-C: Percent Change at Day 4 (n = 9)	-14.37 (± 10.830)			
HDL-C: Percent Change at Week 1 (n = 9)	-23.34 (± 10.783)			
HDL-C: Percent Change at Week 2 (n = 9)	-28.75 (± 8.458)			
HDL-C: Percent Change at Week 3 (n = 9)	-36.96 (± 16.495)			
HDL-C: Percent Change at Week 4 (n = 9)	-35.24 (± 16.212)			
HDL-C: Percent Change at Week 5 (n = 8)	-29.74 (± 14.240)			



HDL-C: Percent Change at Week 6 (n = 9)	-37.88 (± 15.864)			
HDL-C: Percent Change at Week 8 (n = 9)	-25.42 (± 23.199)			
HDL-C: Percent Change at Week 10 (n = 9)	-24.57 (± 22.409)			
HDL-C: Percent Change at Week 12 (n = 9)	-13.59 (± 23.189)			
HDL-C: Percent Change at Week 13 (n = 2)	-24.48 (± 6.243)			
HDL-C: Percent Change at Week 14 (n = 9)	-16.81 (± 14.822)			
HDL-C: Percent Change at Week 15 (n = 2)	-26.97 (± 4.895)			
HDL-C: Percent Change at Week 16 (n = 9)	-12.03 (± 16.026)			
HDL-C: Percent Change at Week 17 (n = 2)	-28.34 (± 8.393)			
HDL-C: Percent Change at Week 18 (n = 7)	-1.05 (± 24.171)			
HDL-C: Percent Change at Week 20 (n = 2)	-25.39 (± 22.187)			
HDL-C: Percent Change at Week 22 (n = 7)	3.78 (± 20.466)			
HDL-C: Percent Change at Week 23 (n = 2)	-11.56 (± 12.094)			
HDL-C: Percent Change at Week 25 (n = 2)	8.41 (± 12.698)			
HDL-C: Percent Change at Week 26 (n = 6)	-12.00 (± 11.109)			
TG: Percent Change at Day 4 (n = 9)	-29.61 (± 18.562)			
TG: Percent Change at Week 1 (n = 9)	-23.41 (± 20.150)			
TG: Percent Change at Week 2 (n = 9)	-17.19 (± 18.735)			
TG: Percent Change at Week 3 (n = 9)	-44.38 (± 19.223)			
TG: Percent Change at Week 4 (n = 9)	-46.57 (± 17.014)			
TG: Percent Change at Week 5 (n = 8)	-44.49 (± 16.583)			
TG: Percent Change at Week 6 (n = 9)	-40.03 (± 26.830)			
TG: Percent Change at Week 8 (n = 9)	-30.69 (± 24.800)			
TG: Percent Change at Week 10 (n = 9)	-31.40 (± 16.697)			
TG: Percent Change at Week 12 (n = 9)	-35.38 (± 25.014)			
TG: Percent Change at Week 13 (n = 2)	-35.11 (± 26.733)			
TG: Percent Change at Week 14 (n = 9)	-23.51 (± 28.335)			
TG: Percent Change at Week 15 (n = 2)	-27.77 (± 55.240)			
TG: Percent Change at Week 16 (n = 9)	-6.70 (± 40.326)			
TG: Percent Change at Week 17 (n = 2)	-42.09 (± 22.941)			
TG: Percent Change at Week 18 (n = 7)	23.13 (± 55.349)			

TG: Percent Change at Week 20 (n = 2)	-26.30 (± 11.945)			
TG: Percent Change at Week 22 (n = 7)	8.86 (± 43.819)			
TG: Percent Change at Week 23 (n = 2)	-30.58 (± 6.662)			
TG: Percent Change at Week 25 (n = 2)	-13.62 (± 21.582)			
TG: Percent Change at Week 26 (n = 6)	-1.60 (± 33.318)			
Apo A-1: Percent Change at Week 2 (n = 9)	-24.37 (± 12.794)			
Apo A-1: Percent Change at Week 3 (n = 9)	-36.47 (± 16.930)			
Apo A-1: Percent Change at Week 4 (n = 9)	-38.54 (± 8.906)			
Apo A-1: Percent Change at Week 5 (n = 8)	-31.91 (± 11.491)			
Apo A-1: Percent Change at Week 6 (n = 9)	-34.72 (± 12.342)			
Apo A-1: Percent Change at Week 8 (n = 9)	-29.03 (± 14.765)			
Apo A-1: Percent Change at Week 12 (n = 9)	-11.85 (± 25.176)			
Apo A-1: Percent Change at Week 14 (n = 9)	-17.65 (± 13.824)			
Apo A-1: Percent Change at Week 16 (n = 9)	-9.86 (± 14.372)			
Apo A-1: Percent Change at Week 18 (n = 7)	-1.16 (± 19.598)			
Apo A-1: Percent Change at Week 20 (n = 2)	-22.15 (± 7.965)			
Apo A-1: Percent Change at Week 22 (n = 7)	4.21 (± 17.857)			
Apo A-1: Percent Change at Week 23 (n = 2)	-21.22 (± 7.959)			
Apo A-1: Percent Change at Week 26 (n = 6)	-9.68 (± 11.250)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Percent Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period
-----------------	---

End point description:

Percent change was reported in HDL-C, TG and Apo A-1 from baseline (week 26) up to week 214. HDL-C, TG and Apo A-1 were measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least one post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for the endpoint at a given time point. (ET= Early Termination; EOS = End of Study)

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Week 26) up to Week 214

End point values	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: Percent change				
arithmetic mean (standard deviation)				
HDL-C: Percent change at Week 27 (n= 8)	-21.47 (± 11.815)			
HDL-C: Percent change at Week 28 (n= 8)	-27.60 (± 11.485)			
HDL-C: Percent change at Week 29 (n= 8)	-26.51 (± 16.584)			
HDL-C: Percent change at Week 30 (n= 7)	-27.57 (± 14.566)			
HDL-C: Percent change at Week 31 (n= 8)	-32.81 (± 18.939)			
HDL-C: Percent change at Week 32 (n= 8)	-32.72 (± 14.684)			
HDL-C: Percent change at Week 34 (n= 8)	-34.60 (± 15.971)			
HDL-C: Percent change at Week 36 (n= 8)	-31.14 (± 18.695)			
HDL-C: Percent change at Week 38 (n= 8)	-18.57 (± 15.411)			
HDL-C: Percent change at Week 39 (n= 6)	-32.09 (± 16.062)			
HDL-C: Percent change at Week 40 (n= 6)	-36.25 (± 9.327)			
HDL-C: Percent change at Week 41 (n= 6)	-39.14 (± 13.804)			
HDL-C: Percent change at Week 42 (n= 6)	-38.31 (± 10.670)			
HDL-C: Percent change at Week 44 (n= 8)	-37.01 (± 12.049)			
HDL-C: Percent change at Week 46 (n= 8)	-32.77 (± 13.829)			
HDL-C: Percent change at Week 50 (n= 8)	-25.17 (± 17.957)			
HDL-C: Percent change at Week 54 (n= 8)	-20.16 (± 18.657)			
HDL-C: Percent change at Week 58 (n= 6)	-10.87 (± 14.194)			
HDL-C: Percent change at Week 70 (n= 4)	-24.67 (± 15.473)			
HDL-C: Percent change at Week 82 (n= 4)	-17.56 (± 10.574)			
HDL-C: Percent change at Week 94 (n= 1)	-13.95 (± 99999)			
HDL-C: Percent change at Week 106 (n= 1)	0.00 (± 99999)			
HDL-C: Percent change at ET (n= 8)	-15.08 (± 21.569)			

HDL-C: Percent change at EOS (n= 3)	-0.78 (± 27.385)			
Triglycerides: Percent change at Week 27 (n= 8)	-38.62 (± 26.036)			
Triglycerides: Percent change at Week 28 (n= 8)	-41.76 (± 27.247)			
Triglycerides: Percent change at Week 29 (n= 8)	-41.17 (± 18.721)			
Triglycerides: Percent change at Week 30 (n= 7)	-38.82 (± 23.649)			
Triglycerides: Percent change at Week 31 (n= 8)	-44.86 (± 28.212)			
Triglycerides: Percent change at Week 32 (n= 8)	-45.33 (± 23.671)			
Triglycerides: Percent change at Week 34 (n= 8)	-28.58 (± 23.643)			
Triglycerides: Percent change at Week 36 (n= 8)	-25.89 (± 36.606)			
Triglycerides: Percent change at Week 38 (n= 8)	-24.32 (± 25.386)			
Triglycerides: Percent change at Week 39 (n= 6)	-48.37 (± 26.457)			
Triglycerides: Percent change at Week 40 (n= 6)	-43.36 (± 26.527)			
Triglycerides: Percent change at Week 41 (n= 6)	-46.65 (± 25.386)			
Triglycerides: Percent change at Week 42 (n= 6)	-43.09 (± 29.631)			
Triglycerides: Percent change at Week 44 (n= 8)	-47.98 (± 35.076)			
Triglycerides: Percent change at Week 46 (n= 8)	-37.64 (± 26.234)			
Triglycerides: Percent change at Week 50 (n= 8)	-22.10 (± 27.247)			
Triglycerides: Percent change at Week 54 (n= 8)	-1.08 (± 30.518)			
Triglycerides: Percent change at Week 58 (n= 6)	3.72 (± 25.130)			
Triglycerides: Percent change at Week 70 (n= 4)	-22.28 (± 31.761)			
Triglycerides: Percent change at Week 82 (n= 4)	-36.47 (± 9.998)			
Triglycerides: Percent change at Week 94 (n= 1)	-76.36 (± 99999)			
Triglycerides: Percent change at Week 106 (n= 1)	-57.98 (± 99999)			
Triglycerides: Percent change at ET (n= 8)	-14.52 (± 25.892)			
Triglycerides: Percent change at EOS (n= 3)	30.98 (± 40.511)			
Apo A-1: Percent change at Week 30 (n= 7)	-27.20 (± 12.119)			
Apo A-1: Percent change at Week 34 (n= 8)	-29.05 (± 17.483)			
Apo A-1: Percent change at Week 38 (n= 8)	-11.79 (± 23.939)			
Apo A-1: Percent change at Week 42 (n= 6)	-35.47 (± 9.512)			
Apo A-1: Percent change at Week 44 (n= 8)	-34.28 (± 11.306)			
Apo A-1: Percent change at Week 50 (n= 8)	-21.01 (± 15.471)			

Apo A-1: Percent change at Week 70 (n= 4)	-25.28 (± 11.950)			
Apo A-1: Percent change at Week 82 (n= 4)	-18.98 (± 6.534)			
Apo A-1: Percent change at Week 94 (n= 1)	-22.45 (± 99999)			
Apo A-1: Percent change at Week 106 (n= 1)	3.06 (± 99999)			
Apo A-1: Percent change at ET (n= 8)	-9.63 (± 25.308)			
Apo A-1: Percent change at EOS (n= 3)	11.27 (± 25.093)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period

End point title	Absolute Change in High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), and Apolipoprotein A-1 (Apo A-1) from Baseline (Week 26) to Week 214 in the Open Label Extension (OLE) Period			
End point description:	Absolute change was reported in HDL-C, TG and Apo A-1 from baseline (week 26) up to week 214. The efficacy analysis set included all subjects in the SAF who had baseline and at least one post-baseline measure of the lipid panel in the main study period. Here, "n" signifies those subjects who were evaluable for this endpoint at a given time point. (ET= Early Termination; EOS = End of Study)			
End point type	Secondary			
End point timeframe:	Baseline (Week 26) up to Week 214			

End point values	REGN1500 300 mg SC/20 mg/kg IV			
Subject group type	Reporting group			
Number of subjects analysed	8			
Units: mg/dL				
arithmetic mean (standard deviation)				
HDL-C: Change at Week 27 (n= 8)	-8.78 (± 5.736)			
HDL-C: Change at Week 28 (n= 8)	-12.08 (± 7.244)			
HDL-C: Change at Week 29 (n= 8)	-11.44 (± 7.858)			
HDL-C: Change at Week 30 (n= 7)	-13.29 (± 9.270)			
HDL-C: Change at Week 31 (n= 8)	-13.94 (± 8.655)			
HDL-C: Change at Week 32 (n= 8)	-14.11 (± 8.163)			

HDL-C: Change at Week 34 (n= 8)	-15.10 (± 9.167)			
HDL-C: Change at Week 36 (n= 8)	-14.14 (± 10.426)			
HDL-C: Change at Week 38 (n= 8)	-8.89 (± 7.513)			
HDL-C: Change at Week 39 (n= 6)	-14.02 (± 8.023)			
HDL-C: Change at Week 40 (n= 6)	-15.90 (± 7.171)			
HDL-C: Change at Week 41 (n= 6)	-17.17 (± 8.262)			
HDL-C: Change at Week 42 (n= 6)	-16.65 (± 7.148)			
HDL-C: Change at Week 44 (n= 8)	-15.83 (± 8.167)			
HDL-C: Change at Week 46 (n= 8)	-14.85 (± 10.173)			
HDL-C: Change at Week 50 (n= 8)	-12.25 (± 10.985)			
HDL-C: Change at Week 54 (n= 8)	-9.06 (± 9.107)			
HDL-C: Change at Week 58 (n= 6)	-5.42 (± 6.058)			
HDL-C: Change at Week 70 (n= 4)	-10.83 (± 10.448)			
HDL-C: Change at Week 82 (n= 4)	-6.28 (± 2.655)			
HDL-C: Change at Week 94 (n= 1)	-4.20 (± 99999)			
HDL-C: Change at Week 106 (n= 1)	0.00 (± 99999)			
HDL-C: Percent change at ET (n= 8)	-7.86 (± 8.258)			
HDL-C: Change at EOS (n= 3)	-1.67 (± 10.698)			
Triglycerides: Change at Week 27 (n= 8)	-31.19 (± 28.590)			
Triglycerides: Change at Week 28 (n= 8)	-36.28 (± 30.630)			
Triglycerides: Change at Week 29 (n= 8)	-32.86 (± 25.188)			
Triglycerides: Change at Week 30 (n= 7)	-32.37 (± 30.475)			
Triglycerides: Change at Week 31 (n= 8)	-39.04 (± 30.169)			
Triglycerides: Change at Week 32 (n= 8)	-37.83 (± 30.808)			
Triglycerides: Change at Week 34 (n= 8)	-25.41 (± 26.559)			
Triglycerides: Change at Week 36 (n= 8)	-24.66 (± 28.139)			
Triglycerides: Change at Week 38 (n= 8)	-21.13 (± 25.190)			
Triglycerides: Change at Week 39 (n= 6)	-40.27 (± 32.803)			
Triglycerides: Change at Week 40 (n= 6)	-37.30 (± 33.559)			
Triglycerides: Change at Week 41 (n= 6)	-39.37 (± 33.251)			
Triglycerides: Change at Week 42 (n= 6)	-37.62 (± 33.724)			

Triglycerides: Change at Week 44 (n= 8)	-42.25 (± 32.682)			
Triglycerides: Change at Week 46 (n= 8)	-31.53 (± 28.209)			
Triglycerides: Change at Week 50 (n= 8)	-20.00 (± 27.720)			
Triglycerides: Change at Week 54 (n= 8)	-6.40 (± 26.869)			
Triglycerides: Change at Week 58 (n= 6)	-3.53 (± 21.753)			
Triglycerides: Change at Week 70 (n= 4)	-21.23 (± 35.614)			
Triglycerides: Change at Week 82 (n= 4)	-26.33 (± 21.457)			
Triglycerides: Change at Week 94 (n= 1)	-88.50 (± 99999)			
Triglycerides: Change at Week 106 (n= 1)	-67.20 (± 99999)			
Triglycerides: Change at ET (n= 8)	-11.71 (± 21.343)			
Triglycerides: Change at EOS (n= 3)	30.67 (± 35.390)			
Apo A-1: Change at Week 30 (n= 7)	-34.4 (± 20.18)			
Apo A-1: Change at Week 34 (n= 8)	-35.1 (± 24.70)			
Apo A-1: Change at Week 38 (n= 8)	-18.0 (± 26.54)			
Apo A-1: Change at Week 42 (n= 6)	-43.7 (± 15.71)			
Apo A-1: Change at Week 44 (n= 8)	-39.4 (± 18.12)			
Apo A-1: Change at Week 50 (n= 8)	-26.9 (± 23.56)			
Apo A-1: Change at Week 70 (n= 4)	-30.3 (± 20.12)			
Apo A-1: Change at Week 82 (n= 4)	-21.0 (± 5.83)			
Apo A-1: Change at Week 94 (n= 1)	-22.0 (± 99999)			
Apo A-1: Change at Week 106 (n= 1)	3.0 (± 99999)			
Apo A-1: Change at ET (n= 8)	-15.6 (± 24.34)			
Apo A-1: Change at EOS (n= 3)	7.0 (± 24.98)			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Absolute Change in Apolipoprotein CIII (Apo CIII) from Baseline (Week 0) Over Time in the Main Study Period

End point title	Absolute Change in Apolipoprotein CIII (Apo CIII) from Baseline (Week 0) Over Time in the Main Study Period
-----------------	---

End point description:

Absolute change was reported in Apo CIII from baseline (week 0) up to week 16. The efficacy analysis set included all subjects in the SAF who had baseline and at least 1 post-baseline measure of the lipid panel in the main study period. Here, "n" signifies the subjects who were evaluable for this endpoint at a given time point.

End point type	Secondary
End point timeframe:	
Baseline (Week 0) up to Week 16	

<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: mg/dL				
arithmetic mean (standard deviation)				
Apo CIII: Change at Day 4 (n = 9)	-3.729 (± 1.6905)			
Apo CIII: Change at Week 1 (n = 9)	-4.296 (± 1.9829)			
Apo CIII: Change at Week 2 (n = 9)	-4.301 (± 2.2542)			
Apo CIII: Change at Week 5 (n = 8)	-6.000 (± 2.8541)			
Apo CIII: Change at Week 6 (n = 1)	-8.380 (± 99999)			
Apo CIII: Change at Week 12 (n = 9)	-3.772 (± 2.8443)			
Apo CIII: Change at Week 14 (n = 9)	-3.866 (± 3.7327)			
Apo CIII: Change at Week 16 (n = 9)	-2.757 (± 4.4877)			

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change in Apolipoprotein CIII (Apo CIII) from Baseline (Week 0) Over Time in the Main Study Period

End point title	Percent Change in Apolipoprotein CIII (Apo CIII) from Baseline (Week 0) Over Time in the Main Study Period
End point description:	
Percent change was reported in Apo CIII from baseline (week 0) up to week 16. Apo CIII was measured using conventional units mg/dL. The efficacy analysis set included all subjects in the SAF who had baseline and at least one post-baseline measure of the lipid panel in the main study period. Here, "n" signifies the subjects who were evaluable for this endpoint at a given time point.	
End point type	Secondary
End point timeframe:	
Baseline (Week 0) to Week 16	



<b>End point values</b>	REGN1500 250 mg SC/15 mg/kg IV/450 mg SC			
Subject group type	Reporting group			
Number of subjects analysed	9			
Units: Percent Change				
arithmetic mean (standard deviation)				
Apo CIII: Percent Change at Day 4 (n = 9)	-46.59 (± 22.129)			
Apo CIII: Percent Change at Week 1 (n = 9)	-55.43 (± 18.541)			
Apo CIII: Percent Change at Week 2 (n = 9)	-56.57 (± 24.815)			
Apo CIII: Percent Change at Week 5 (n = 8)	-75.44 (± 9.667)			
Apo CIII: Percent Change at Week 6 (n = 1)	-91.48 (± 99999)			
Apo CIII: Percent Change at Week 12 (n = 9)	-49.07 (± 25.517)			
Apo CIII: Percent Change at Week 14 (n = 9)	-40.67 (± 44.674)			
Apo CIII: Percent Change at Week 16 (n = 9)	-28.30 (± 54.676)			

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

All adverse events (AEs) were collected from signature of the informed consent form up to the final visit regardless of seriousness or relationship to investigational product.

Adverse event reporting additional description:

During the main study period, the safety analysis set (SAF) was defined as all enrolled subjects who received at least 1 dose or part of a dose. For OLE, the SAF was defined as all enrolled subjects who received at least 1 dose or part of a dose in the OLE period. The SAF in both study periods was based on the treatment received (as treated).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	17.0

### Reporting groups

Reporting group title	OLE Period: REGN1500 300 mg SC/20 mg/kg IV
-----------------------	--

Reporting group description:

Subjects received REGN1500 a SC injection of 300 mg at Week 26 (Day 183), 27 (Day 190), 28 (Day 197) and 29 (Day 204) followed by IV injection of 20 mg/kg at Week 38 (Day 267) and every 12 weeks starting at Week 58 (Day 407) through Week 178 (Day 1247) in open-label extension period. Subjects were to be followed for a period of 24 weeks (through Week 214 [Day 1499]) after the last dose of study drug in the OLE treatment period.

Reporting group title	Main Study Period: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
-----------------------	---

Reporting group description:

Subjects received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled subjects received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Subjects were followed for a period of 24 weeks (through Week 26 [Day 183]) after the last dose of study drug in the main study period.

Serious adverse events	OLE Period: REGN1500 300 mg SC/20 mg/kg IV	Main Study Period: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC	
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 8 (25.00%)	1 / 9 (11.11%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Cardiac disorders			
Coronary artery disease			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery stenosis			

subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Bronchospasm			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	OLE Period: REGN1500 300 mg SC/20 mg/kg IV	Main Study Period: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 8 (100.00%)	9 / 9 (100.00%)	
Vascular disorders			
Flushing			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	2	
General disorders and administration site conditions			
Chest discomfort			
subjects affected / exposed	1 / 8 (12.50%)	1 / 9 (11.11%)	
occurrences (all)	1	1	
Chest pain			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Fatigue			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Injection site haematoma			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Influenza like illness			
subjects affected / exposed	2 / 8 (25.00%)	2 / 9 (22.22%)	
occurrences (all)	2	3	

Injection site haemorrhage subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 2	
Local swelling subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Oedema peripheral subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Immune system disorders Food allergy subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2	0 / 9 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Bronchospasm subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Cough subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Epistaxis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Rhinalgia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Upper-Airway cough syndrome			

subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Psychiatric disorders Insomnia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Investigations Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)  Crystal urine present subjects affected / exposed occurrences (all)  Liver function test abnormal subjects affected / exposed occurrences (all)  Transaminases increased subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2  0 / 8 (0.00%) 0  0 / 8 (0.00%) 0  1 / 8 (12.50%) 1	1 / 9 (11.11%) 3  1 / 9 (11.11%) 1  1 / 9 (11.11%) 1  0 / 9 (0.00%) 0	
Injury, poisoning and procedural complications Crush injury subjects affected / exposed occurrences (all)  Contusion subjects affected / exposed occurrences (all)  Procedural hypotension subjects affected / exposed occurrences (all)  Thermal burn subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1  1 / 8 (12.50%) 1  0 / 8 (0.00%) 0  0 / 8 (0.00%) 0	0 / 9 (0.00%) 0  0 / 9 (0.00%) 0  1 / 9 (11.11%) 1  1 / 9 (11.11%) 1	
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 9 (11.11%) 1	

Headache subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Memory impairment subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 9 (11.11%) 1	
Eye disorders Corneal opacity subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Eye inflammation subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Gastrointestinal disorders Abdominal pain subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 2	0 / 9 (0.00%) 0	
Diarrhoea subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 6	1 / 9 (11.11%) 2	
Faeces discoloured subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Nausea subjects affected / exposed occurrences (all)	3 / 8 (37.50%) 5	4 / 9 (44.44%) 6	
Vomiting subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 9 (11.11%) 1	
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	

Ecchymosis subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Generalised erythema subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Pruritus allergic subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Rash subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 3	0 / 9 (0.00%) 0	
Renal and urinary disorders Renal failure chronic subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	0 / 9 (0.00%) 0	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)	4 / 8 (50.00%) 8	4 / 9 (44.44%) 6	
Muscle spasms subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	1 / 9 (11.11%) 1	
Musculoskeletal pain subjects affected / exposed occurrences (all)	2 / 8 (25.00%) 3	2 / 9 (22.22%) 2	
Myalgia subjects affected / exposed occurrences (all)	0 / 8 (0.00%) 0	2 / 9 (22.22%) 2	
Neck pain subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 9 (11.11%) 1	
Pain in extremity subjects affected / exposed occurrences (all)	1 / 8 (12.50%) 1	1 / 9 (11.11%) 1	
Infections and infestations			

Gastroenteritis			
subjects affected / exposed	1 / 8 (12.50%)	1 / 9 (11.11%)	
occurrences (all)	1	2	
Nasopharyngitis			
subjects affected / exposed	3 / 8 (37.50%)	2 / 9 (22.22%)	
occurrences (all)	4	3	
Influenza			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Pharyngitis			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	
Rhinitis			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Sinusitis			
subjects affected / exposed	2 / 8 (25.00%)	1 / 9 (11.11%)	
occurrences (all)	2	2	
Upper respiratory tract infection			
subjects affected / exposed	2 / 8 (25.00%)	0 / 9 (0.00%)	
occurrences (all)	3	0	
Urinary tract infection			
subjects affected / exposed	1 / 8 (12.50%)	0 / 9 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Hypokalaemia			
subjects affected / exposed	0 / 8 (0.00%)	1 / 9 (11.11%)	
occurrences (all)	0	1	



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 May 2014	The purpose of this amendment was to include sampling for, and assessment of, low-density lipoprotein receptor (LDLR) function.
01 October 2014	The purpose of this amendment was to: Allow up to 4 patients who are taking stable, background lomitapide to be enrolled; Allow patients with a known history of HIV to be enrolled. Inclusion of these patients will be dependent on their ability to meet entry criteria for CD4 count, viral load, absence of opportunistic infections or tuberculosis, and stability of their antiretroviral therapy; Require more stringent (double-barrier) contraception; Move the required DNA sample for confirmation of diagnosis of homozygous familial hypercholesterolemia from visit 2 (baseline) to visit 1 (screening); Add review of inclusion/exclusion criteria at visit 2 (baseline); Increase the time after the final date of the clinical study report that sub-study samples may be stored and used for research purposes from up to 10 years to up to 15 years; Remove the 1-day window from visit 2 (baseline); Update exposure data from the ongoing phase 1 study; Clarify the end of treatment and end of study visits for patients who prematurely discontinue from the study; Make minor editorial changes
24 February 2015	The purpose of this amendment was to: Exclude women of childbearing potential from eligibility in the study, in agreement with the Food and Drug Administration (FDA), based on safety findings from a pilot embryo-fetal toxicity study with REGN1500; Include measurement of follicle-stimulating hormone (FSH) at screening; Remove urine pregnancy testing; Allow for patients to be rescreened on a case-by-case basis; Allow for replacement of patients who discontinued prior to visit 4
02 November 2015	The purpose of this amendment was to: Remove the 4 weekly 450 mg SC doses; Extend the duration of follow-up/observation period to 24 weeks after the last dose of study drug to ensure patients are monitored for the duration of drug exposure; Allow women of childbearing potential to participate in the study; Update exclusion criteria; Update prohibited and permitted concomitant medications
14 May 2016	The purpose of this amendment was to: Add an open-label extension (OLE) period; Update the protocol with new clinical and preclinical data; Revise the PK and ADA variables; Revise the statistical hypothesis and justification of sample size; Increase the number and region of the study sites; Remove the 250 mg/kg subcutaneous (SC) dose from the main period of the study; Include a possible interim analysis; Allow the required DNA sample to be collected at visit 1a or visit 1; Revise the secondary endpoints to reflect the removal of the 4 weekly 450 mg SC doses that was implemented in Amendment 4; Clarify pharmacokinetic (PK) sampling times in the main study period; Clarify anti-drug antibody (ADA) sampling; Update definition of baseline and clarify use of data from unscheduled assessments; Update the safety section of the protocol with the new language in the updated protocol template; State that serum pregnancy testing in the main period of the study will only be performed in women of childbearing potential (WOCBP); Make miscellaneous editorial/formatting revisions

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

At the time patients completed the main study, the open-label extension (OLE) study was not yet open to enrollment. Therefore, there was a lag of between 168 days to 586 days between the end of the main study and the start of the OLE study.

Notes: